Table 4.

Costs incremental health outcomes and cost-utility of pre-referral antimalarial treatments by healthcare provider

Scenario	Intervention	Costs for a cohort of 1000 children ($)	DALYs	DALYs averted	Incremental cost ($)	ICER ($ per DALY averted)
Base model	No treatment	0.89	20,122	–	–	–
	CHW	85,491	4587	15,535	85,490	5.50
	PHF	88,961	7512	12,610	88,960	7.05
	THF	123,711	2186	17,936	123,710	6.90
Probabilistic sensitivity analysis	No treatment	0.88 [0.88–0.88]	19,529 [15,315, 24,737]	–	–	–
	CHW	68,428 [43,362, 100,703]	5413 [3091, 8430]	13,276 [9534, 17,684]	68,427 [43,361, 100,702]	5.11 [3.01, 8.21]
	PHF	73,825 [47,531, 103,875]	8328 [5030, 12,531]	9993 [6180, 14,429]	73,825 [47,530, 103,874]	7.30 [5.30, 11.20]
	THF	114,903 [91,842, 145,168]	3111 [1801, 5005]	15,801 [11,990, 20,375]	114,902 [91,841, 145,167]	7.14 [5.10, 10.92]

CHW community healthworker, PHF primary health facility, THF tertiary health facility, ICER incremental cost-utility ratio, cost cost for treating one child